The form of dietary conjugated linoleic acid does not influence plasma and liver triacylglycerol concentrations in Syrian golden hamsters.
Several studies have shown that conjugated linoleic acid (CLA) supplementation can improve the plasma lipid profile and thereby probably decrease the risk for development of atherosclerosis. The aim of the present study was to compare the effects on plasma and organ lipids of different dietary forms of CLA: triacylglycerol (TAG), diacylglycerol (DAG), monoacylglycerol (MAG), and fatty acid ethyl esters (FAEEs). DAG-, MAG-, and FAEE-CLA were produced by enzymatic interesterifications and all supplements were composed of a 1:1 mixture of the 2 major CLA isomers: cis-9, trans-11 and trans-10, cis-12. Male Syrian Golden hamsters were fed mildly atherogenic diets (10 g butter/100 g, 0.1 g cholesterol/100 g) supplemented with 0.5 g CLA/100 g or without CLA (control) for 8 wk. Liver weights were greater in the TAG- and FAEE-CLA groups than in the control group. In general, the form of CLA did not differentially affect plasma or liver cholesterol or plasma lipoprotein cholesterol concentrations, but only the TAG-CLA group had a higher final plasma TAG concentration than the control group. Both CLA isomers were incorporated into plasma, livers, and spleens. The results of the present study suggest that the form in which CLA is supplemented in the diet does not affect hamster plasma and liver TAG concentrations. The TAG-CLA form, a frequently used form of supplemental CLA, increases plasma TAG concentrations. If similar effects occur in humans, supplemental TAG-CLA cannot be considered to be beneficial given the relation between plasma TAG and the development of atherosclerosis.
Porsgaard
Trine
T
Biochemistry and Nutrition Group, BioCentrum-DTU, Technical University of Denmark, 2800 Lyngby, Denmark.
Xu
Xuebing
X
Mu
Huiling
H
D000818:Animals; D002851:Chromatography, High Pressure Liquid; D006224:Cricetinae; D004041:Dietary Fats / Q000008:administration & dosage / Q000378:metabolism / Q000494:pharmacology*; D007536:Isomerism; D044243:Linoleic Acids, Conjugated / Q000008:administration & dosage / Q000378:metabolism / Q000494:pharmacology*; D008055:Lipids / Q000097:blood*; D008099:Liver / Q000187:drug effects* / Q000378:metabolism; D008297:Male; D008647:Mesocricetus; D013154:Spleen / Q000187:drug effects / Q000378:metabolism; D014280:Triglycerides / Q000097:blood* / Q000378:metabolism
D004041:Dietary Fats; D044243:Linoleic Acids, Conjugated; D008055:Lipids; D014280:Triglycerides